Industry Biopharmaceutical
Sector New drug discovery
Fiscal year end September 30
Shares issued and outstanding 70,030, 620 *
Stock purchase warrants 500,000 **
Stock options 11,005,199 **
Fully diluted 81,535,819**
Cash  $75.9 million*
Debt Nil**
Trading symbol AVXL
52-week range $28.70 – $3.42*
Financial statements and filings Anavex’s filings can be found on EDGAR.
Investor relations 1-844-689-3939
ir@anavex.com
Transfer agent Nevada Agency and Trust
50 West Liberty Street, Suite 880
Reno, Nevada 89501
Tel: (775) 322-0626
Fax: (775) 322-5623
Transfer agent email: info@natco.org
Resident Agent email: corpserve@natco.org
Web site: www.natco.org
* As of May 11, 2021

** As of March 31, 2021

Forms – Reverse Stock Split
Internal Revenue Service (United States) – Form 8937.
Form_8937_(signed)